Table 4 Efficacy outcomes by prior bortezomib or lenalidomide treatment and prior therapy line
Prior bortezomib exposure | No prior bortezomib exposure | Prior lenalidomide exposure | No prior lenalidomide exposure | |||||
|---|---|---|---|---|---|---|---|---|
Kd (n=250) | Vd (n=252) | Kd (n=214) | Vd (n=213) | Kd (n=177) | Vd (n=177) | Kd (n=287) | Vd (n=288) | |
1–3 prior lines, n | 250 | 252 | 214 | 213 | 177 | 177 | 287 | 288 |
Median PFS, months | 15.6 | 8.1 | NE | 11.2 | 12.9 | 7.3 | 22.2 | 10.2 |
HR for progression, Kd vs Vd (95% CI) | 0.56 (0.44–0.73) | 0.48 (0.35–0.66) | 0.69 (0.52–0.92) | 0.43 (0.32–0.56) | ||||
ORR, % | 71.2 | 60.3 | 83.6 | 65.3 | 70.1 | 59.3 | 81.2 | 64.6 |
1 prior line, n | 97 | 98 | 134 | 131 | 51 | 45 | 180 | 184 |
Median PFS, months | 18.7 | 8.7 | NE | 11.2 | 15.6 | 10.3 | 22.2 | 10.1 |
HR for progression, Kd vs Vd (95% CI) | 0.48 (0.31–0.76) | 0.43 (0.28–0.66) | 0.62 (0.33–1.17) | 0.41 (0.29–0.58) | ||||
ORR, % | 78.4 | 64.3 | 83.6 | 65.6 | 82.4 | 64.4 | 81.1 | 65.2 |
2–3 prior lines, n | 153 | 154 | 80 | 82 | 126 | 132 | 107 | 104 |
Median PFS, months | 13.1 | 7.4 | 15.7 | 9.4 | 9.7 | 6.6 | NE | 10.4 |
HR for progression, Kd vs Vd (95% CI) | 0.62 (0.45–0.85) | 0.56 (0.36–0.89) | 0.73 (0.53–1.01) | 0.45 (0.29–0.70) | ||||
ORR, % | 66.7 | 57.8 | 83.8 | 64.6 | 65.1 | 57.6 | 81.3 | 63.5 |
